Zogenix Zogenix

Patients & Community

UCB acquired Zogenix and FINTEPLA on March 7, 2022. The acquisition is consistent with UCB’s sustainable patient value strategy and continued commitment to providing world-leading patient value to all people living with epilepsy, with an increasing focus on creating value and new solutions that address the unmet needs of people with certain specialized or rare types of epilepsy, where few or no options exist.

Dravet Syndrome

A rare and severe epilepsy
Dravet syndrome is a rare, severe, treatment-resistant epilepsy syndrome with onset in infancy and serious neurodevelopmental, motor, cognitive, and behavioral consequences that persist into adulthood. Studies have reported an incidence rate for Dravet syndrome of approximately one per 16,000 live births with onset occurring within the first year of life.
  • Clinical Studies – Zogenix is not currently enrolling patients in studies for Dravet syndrome.
  • EAP – We offer a limited expanded access program (also known as “compassionate use” or “early access”) for our investigational therapy ZX008. Requests for access to experimental therapies must be made by a qualified and licensed physician. Learn More
  • Disease – For more information about the US Dravet Syndrome Foundation, click here. For more information about the Dravet Syndrome European Federation, click here.
  • Additional Resources – For more information about Dravet Syndrome, please see the Dravet Syndrome, and Dravet Syndrome Caregiver factsheets

Lennox-Gastaut Syndrome (LGS)

A rare and severe epilepsy
LGS is also a form of rare, severe form of epilepsy marked by frequent and prolonged seizures, with peak onset between ages 3 and 5. LGS impacts approximately 14,500 to 18,500 children in the U.S.
  • Clinical Studies – Zogenix is not currently enrolling patients in studies for LGS.
  • Disease – For more information about the US LGS Foundation, please visit www.lgsfoundation.org.
  • Additional Resources – For more information about LGS, please see the LGS factsheet.

CDKL5 Deficiency Disorder (CDD)

A rare and severe epilepsy
CDKL5 deficiency disorder is a rare developmental epileptic encephalopathy caused by mutations in the CDKL5 gene which can manifest in a broad range of clinical symptoms and severity. The hallmarks are early-onset, intractable epilepsy and neurodevelopmental delay impacting cognitive, motor, speech, and visual function. Although rare, the occurrence is believed to be ~1:40,000 -60,000 live births, making it one of the most common forms of genetic epilepsy.[i]

 

 

[i] https://www.cdkl5.com/about-cdkl5/

TK2 Deficiency

A progressive, devastating mitochondrial disease.
Thymidine kinase 2 deficiency (TK2d) is a genetic disorder that results in mitochondrial dysfunction, leading to inadequate energy production in cells. TK2d onset occurs across all ages and causes progressive and severe muscle weakness, respiratory insufficiency, loss of motor function, and is often fatal. There are currently no approved therapies for this disease.
  • Clinical Studies – Zogenix is not yet enrolling for Phase 3 trials of MT1621, its investigational treatment for TK2 deficiency.
  • Registry – Take on TK2D –Whether you’re living with an MDS, have been diagnosed with TK2d, or are a parent, caregiver, or healthcare professional (HCP) who wants to learn more about MDS and TK2d, join the registry so we can all take on TK2d together.
  • Disease – For more information about TK2 deficiency, please visit tk2d.com. Or visit the United Mitochondrial Disease Foundation at https://www.umdf.org/
  • Additional Resources – Understanding TK2d